Page 102 - MemoriaCIBER2019-ENG

102
CIBER Annual report 2019
Programmes
Chronic Respiratory Diseases
Coordinator: Juan Fernando Masa Jiménez Asthma Line
• CIBERES ASTHMA cohort: ongoing studies derived from the cohort of patients created by the Line, currently consisting of 512 patients with a minimum follow-up of three years. Potentially useful biomarkers for the diagnosis, activity and classification of the disease and its relationship with phenotypic expression and response to treatment are validated.
• Participation in an international E-Phocas project with the aim of studying different asthmatic phenotypes from patients with occupational asthma
COPD Line
• Active follow-up cohorts continue appropriately and closed ones are in the process of preparing publica- tions.
• Biomarker evaluation; BIOMEPOC is in the process of writing up manuscripts. Finishing Blind analysis of clusters based on proteomic signatures is currently being completed.
• BIOEARLY COPD has all the samples in the PRBB-IMIM BIOBANK. Funds are being secured for their analysis.
• The therapeutic response evaluation project has begun field work with 12 centres nationwide.
Cancer Line
• Obstructive sleep apnea and nocturnal hypoxemia are associated with an increasedrisk of lung cancer. Autores: Seijo LM, Pérez-Warnisher MT, Giraldo-Cadavid LF, Oliveros H, Cabezas E,Troncoso MF, Gómez T, Melchor R, Pinillos EJ, El Hachem A, Gotera C, Rodriguez P,González-Mangado N, Peces-Barba GJournal: Sleep medicinePublication date: 2019-11-01DOI: 10.1016/j.sleep.2019.05.011.
• Sleep disordered breathing and nocturnal hypoxemia are very prevalent in a lungcancer screening popu- lation and may condition lung cancer screening findings: results of theprospective Sleep Apnea In Lung Cancer Screening (SAILS) study. Autores: Pérez-Warnisher MT, Cabezas E, Troncoso MF, Gómez T, Melchor R, Pinillos EJ, ElHachem A, Gotera C, Rodriguez P, Mahíllo I, González-Mangado N, Peces-Barba G, Seijo LM- Journal: Sleep medicinePublication date: 2019-02-01DOI: 10.1016/j.sleep.2018.10.020.